Thymus Transplantation Safety-Efficacy

Status Approved for marketing

Clinical Trial Summary

Complete DiGeorge anomaly (cDGA) is a disorder in which there is no thymus function. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection. Without successful treatment, patients with cDGA must remain in reverse isolation to prevent infection and subsequent death. Cultured thymus tissue with and without immunosuppression (drugs given before and after implantation) has resulted in the development of good T cell function in subjects with complete DiGeorge anomaly. This expanded access study continues cultured thymus tissue safety and efficacy research for the treatment of complete DiGeorge anomaly. Eligible participants receive cultured thymus tissue. Immune function testing is continued for one year post-implantation.

Clinical Trial Description

Complete DiGeorge anomaly (cDGA) is a congenital disorder characterized by athymia. Without successful treatment, patients with cDGA must remain in reverse isolation to prevent infection and subsequent death. In patients with cDGA, implantation of cultured thymus tissue with and without immunosuppression has resulted in diverse T cell development and good T cell function. The purpose of this expanded access study is to continue cultured thymus tissue safety and efficacy research for the treatment of athymia in patients with cDGA. Until administration of cultured thymus tissue is FDA approved as standard care for cDGA, research study participation is the only means by which a patient may have access to this potentially life-saving procedure. This protocol includes 4 groups: one for subjects who do not require immunosuppression; and 3 immunosuppression groups for subjects with different T cell function levels to be suppressed adequately. Eligible subjects receive cultured thymus tissue and may undergo an allograft biopsy. Protocol specified studies continue until approximately one year post-implantation. Study participation lasts two years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01220531
Study type	Expanded Access
Source	Enzyvant Therapeutics GmBH
Contact
Status	Approved for marketing
Phase

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00576836` - Thymus Transplantation Dose in DiGeorge #932	Phase 2
Completed	`NCT00004351` - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes	N/A
Terminated	`NCT00395538` - Effects of PTH Replacement on Bone in Hypoparathyroidism	Phase 3
Completed	`NCT02787486` - Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
Completed	`NCT00576407` - Thymus Transplantation in DiGeorge Syndrome #668	Phase 2
Completed	`NCT00105274` - Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study	N/A
Active, not recruiting	`NCT02430584` - Whole Blood Specimen Collection From Pregnant Subjects
Recruiting	`NCT01821781` - Immune Disorder HSCT Protocol	Phase 2
Recruiting	`NCT00556530` - Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
Completed	`NCT00579709` - Thymus Transplantation With Immunosuppression	Phase 1
Completed	`NCT00566488` - Parathyroid and Thymus Transplantation in DiGeorge #931	Phase 1
Terminated	`NCT00278005` - Infection in DiGeorge Following CHD Surgery	N/A
Recruiting	`NCT00005102` - Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome	N/A
Completed	`NCT02381457` - SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.